Sales: $7.4 billion for baby, oral and skin care products. Corporate sales: $67.2 billion. Net income: $9.6 billion.
Key Personnel: Alex Gorsky, chairman and chief executive officer; Sandra E. Peterson, group worldwide chairman.
Major Products: Listerine, Johnson’s Baby, Aveeno and Neutrogena.
New Products: Neutrogena—Naturals Acne Foaming Scrub, Naturals Acne Spot Treatment and Naturals Acne Cream Cleanser; Beach Defense Sunscreen Spray (SPF70 and SPF30), Sunscreen Lotion (SPF70 and SPF30); Pore Refining Daily Cleanser, MoistureSmooth Color Stick, Crease Proof Eye Shadow, Healthy Lengths Mascara, Shine Control Liquid Makeup, Healthy Skin Primer, Shine Control Primer, Ultra Gentle Daily Cleanser, Shine Control Powder; Rapid Tone Repair Moisturizer and Night Moisturizer; Pore Refining Exfoliating Cleanser and Toner. Aveeno—Baby Organic Harvest lotion, Baby Eczema Therapy Moisturizing Cream, Smart Essentials Daily Nourishing Moisturizer with SPF 30, Ageless Vitality Elasticity Recharging System, Living Color, Positively Nourishing Soothing 24-Hour Body Moisturizer, Positively Nourishing Hydrating Body Wash, Pure Renewal Shampoo; Clean & Clear Morning Burst Boost Body Wash and Fruit Infusions Facial Reviving Cleanser. Listerine Total Care Zero. Lubriderm Men’s 3-in-1 Fragrance Free Lotion. RoC Retinol Correxion Sensitive Night Cream and Sensitive Eye Cream.
Comments: Corporate sales rose 3.4% last year, but sales of oral, baby and skin care products fell 3%.
Taking a closer look at these segments, skin care sales fell 2.6% to $3.6 billion, as increased sales of Neutrogena were offset by competition and economic conditions outside the US. Sales of baby care products dropped 3.7% to $2.3 billion due to a decline in US sales and the impact of negative currency exchange rates. The decline was partially offset by sales of hair care products and wipes outside the US. Oral care sales were flat at $1.5 billion. Increased sales of Listerine products outside the US were offset by competitive pressure inside the US.
In November, Alex Gorsky was elected chairman. He succeeded Bill Weldon who retired March 31, 2013.
For the first quarter, the company reported sales rose 8.5% to $17.5 billion. Net income was $3.5 billion. Worldwide consumer product sales rose 2.2% to $3.7 billion as Johnson’s baby care, Listerine mouthwash and Neutrogena skin care products all contributed to the increase. During the quarter, J&J (China) completed the acquisition of Shanghai Elsker Mother & Baby Co., Ltd., which is billed as a well-regarded baby care company with a strong position in the naturals segment.
Last August, the company launched SafetyandCareCommitment.com, an initiative to help consumers better understand all the measures the company takes to make its beauty and baby care products as safe as can be.
“There’s a public discussion underway about the ingredients in beauty care products, and we think it’s important to be part of that,” said Susan Nettesheim, VP of product stewardship and toxicology for Johnson & Johnson Consumer Companies, Inc. “Consumers today expect more information and greater transparency than ever before and we’re always listening to the people who use our products. On this site, we’ll do our best to explain how we make the choices we make, and to show how our plans incorporate consumers’ feedback. We want all consumers to see for themselves how and why every one of our products can be used with peace of mind.”
The SafetyandCareCommitment.com site includes information about how ingredients are selected and evaluated, and provides details on the company’s “gold standard safety assurance process.”
• Is New Jersey the only place for innovation in the US? Fuggetaabout it! Last month, J&J dedlicated the Johnson & Johnson California Innovation Center, one of four regional hubs being established in the world’s leading life science innovation hotspots.The goal of the California Innovation Center is to advance healthcare by catalyzing collaborations in science and technology between regional innovators and the Johnson & Johnson family of companies across a diverse spectrum of early stage innovation.
The center includes business, science and transaction experts who are focused on identifying and building novel early stage collaborations with emerging companies, entrepreneurs and academic centers across western North America, according to J&J.
“The California Innovation Center is part of Johnson & Johnson’s global innovation strategy to advance human health by collaborating with the world’s leading scientists and entrepreneurs,” said Paul Stoffels, M.D., chief scientific officer and worldwide chairman, pharmaceuticals. “We look forward to deepening connections within the west coast life science ecosystem and nurturing healthcare innovation.”